Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Summary

Rhythm Pharmaceuticals is positioned to address a specific form of obesity that Eli Lilly and Novo Nordisk cannot treat, with billionaire investor Stanley Druckenmiller betting on the company's potential in this niche market.